Biocryst Pharmaceuticals Stock Analysis

BioCryst Stock Analysis Notes

About 86.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.61. BioCryst Pharmaceuticals had not issued any dividends in recent years. BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Biocryst Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 358 people. For more info on BioCryst Pharmaceuticals please contact Jon Stonehouse at 919 859 1302 or go to https://www.biocryst.com.

BioCryst Pharmaceuticals Investment Alerts

BioCryst Pharmaceuticals Upcoming and Recent Events

BioCryst Largest EPS Surprises

View All Earnings Estimates

BioCryst Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

BioCryst Stock Institutional Investors

Note, although BioCryst Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

BioCryst Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.57 B.

BioCryst Profitablity

The company has Profit Margin (PM) of (0.3) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.07 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.07.

Management Efficiency

BioCryst Pharmaceuticals has return on total asset (ROA) of (0.0425) % which means that it has lost $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.2537) %, meaning that it created substantial loss on money invested by shareholders. BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.52 in 2024, whereas Return On Tangible Assets are likely to drop (0.46) in 2024. At this time, BioCryst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 24.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 7.6 M in 2024.

Technical Drivers

As of the 24th of November, BioCryst Pharmaceuticals shows the Standard Deviation of 3.16, risk adjusted performance of 0.004, and Mean Deviation of 2.19. BioCryst Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

BioCryst Pharmaceuticals Price Movement Analysis

BioCryst Pharmaceuticals Insider Trading Activities

BioCryst Pharmaceuticals Outstanding Bonds

BioCryst Pharmaceuticals Predictive Daily Indicators

BioCryst Pharmaceuticals Corporate Filings

BioCryst Pharmaceuticals Forecast Models

BioCryst Pharmaceuticals' time-series forecasting models are one of many BioCryst Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioCryst Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how BioCryst Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioCryst shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioCryst Pharmaceuticals. By using and applying BioCryst Stock analysis, traders can create a robust methodology for identifying BioCryst entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BioCryst analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BioCryst analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

BioCryst Pharmaceuticals stock analysis indicators help investors evaluate how BioCryst Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BioCryst Pharmaceuticals shares will generate the highest return on investment. By understating and applying BioCryst Pharmaceuticals stock analysis, traders can identify BioCryst Pharmaceuticals position entry and exit signals to maximize returns.

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.